US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
biotech · Lung Cancer · Non-small Cell Lung Cancer (NSCLC) · RVMD
Revolution Medicines
Revolution Medicines drug portfolio — 28 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
700 Saginaw Dr., Redwood City, California 94063, US HQ
2014 Founded
1,050 Employees
Public company Type
RVMD · NYSE Ticker
Company details
- Status
- Public
- HQ
- 700 Saginaw Dr., Redwood City, California 94063, US
- Founded
- 2014
- Employees
- 1,050
- Programs
- 26
- Drugs
- 28
- Patents
- 36
Revolution Medicines pipeline
Portfolio lens on 28 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Revolution Medicines drug portfolio — 28 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Revolution Medicines in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Revolution Medicines in public FDA and regional records. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Revolution Medicines in public FDA and regional records.
-
US regulatory status: approved.
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Revolution Medicines in public FDA and regional records.
-
Development asset linked to Revolution Medicines in public FDA and regional records.
-
Development asset linked to Revolution Medicines in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Revolution Medicines in public FDA and regional records.
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved. Molecular target: DNA polymerase (alpha/delta/epsilon).
- Target
- DNA polymerase (alpha/delta/epsilon)
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to Revolution Medicines in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
Development asset linked to Revolution Medicines in public FDA and regional records.
-
Development asset linked to Revolution Medicines in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.
- Mechanism
- DNA topoisomerase I inhibitor
-
US regulatory status: approved. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I inhibitor
-
Development asset linked to Revolution Medicines in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
pemetrexed
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Revolution Medicines in public FDA and regional records.
-
Development asset linked to Revolution Medicines in public FDA and regional records.
-
Development asset linked to Revolution Medicines in public FDA and regional records.